Oxyfast

Quick links to important sections

Oxyfast

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Oxyfast

Quick Facts

Property Description
Active ingredient Oxycodone Hydrochloride
Form Immediate-release oral solution (concentrate)
Pharmacological class Opioid Analgesic
Common use Relief of moderate to severe pain
Origin Semi-synthetic opioid

What Type of Medicine is Oxyfast and What is its Composition?

Oxyfast is a potent prescription-only medicine whose active component is Oxycodone Hydrochloride, chemically classified as a semi-synthetic opioid. It belongs to the pharmacological class of Opioid Analgesics and is designated as a Central Nervous System (CNS) Depressant. This single-entity preparation acts systemically, meaning it affects the entire nervous system to interrupt pain signaling.

The core substance, Oxycodone, is derived from the opium alkaloid thebaine. This derivation process results in a substance that is clinically recognized for its high potency when compared to common non-opioid pain relievers. Its principal therapeutic function is to achieve profound analgesia by modulating pain perception centrally.


Understanding Oxyfast: Its Form and General Purpose

Oxyfast is supplied as an immediate-release oral solution (a concentrate) intended for oral administration. This form is specifically chosen to facilitate a rapid onset of action, delivering the active ingredient swiftly into the system.

The general purpose of this medicine is to provide strong, effective relief for moderate to severe pain, such as pain following a surgical procedure. Its formulation as an immediate-release liquid is directly tied to its goal of providing swift symptomatic control, which differentiates it from extended-release preparations. Drugs like Oxycodone are highly effective in providing adequate analgesia for pain that is unresponsive to non-opioid medications.

Regulatory References

  1. MedlinePlus - Oxycodone

What side effects are possible with Oxyfast?

Possible Side Effects and Safety Information

The safety profile for Oxycodone Hydrochloride (Oxyfast) is formally documented by regulatory authorities, classifying adverse reactions primarily by their frequency and the physiological system affected. As a potent opioid analgesic, its use carries specific, serious risks.

Frequency-Classified Adverse Reactions

The most frequently documented effects relate to the central nervous system (CNS) and the gastrointestinal tract. According to regulatory frequency standards:

Classification Common Examples
Very Common (ge 1 in 10) Constipation, Nausea, Vomiting, Somnolence (Drowsiness), Dizziness, Headache, Pruritus (Itching).
Common (ge 1 in 100 to < 1 in 10) Dry mouth, Abdominal pain, Diarrhea, Anxiety, Insomnia, Sweating, Asthenia (Weakness).

Serious Safety Risks and Limitations

Official labels identify critical safety concerns. The most serious risk is Life-Threatening Respiratory Depression, which is a potentially fatal consequence of opioid use, particularly when treatment is initiated or the dose is increased. There is also a significant risk for the development of Drug Dependence, Addiction, and subsequent Withdrawal Syndrome with prolonged use.

Regulatory documents include specific contraindications, such as its prohibition in patients experiencing significant respiratory depression or those with suspected paralytic ileus (gastrointestinal obstruction).

Population-Specific Considerations

Caution is formally advised for specific patient groups. Older adults may exhibit increased sensitivity and risk of CNS and respiratory effects. Similarly, patients with hepatic or renal impairment may require special consideration due to the potential for reduced drug clearance and accumulation in the body, which can increase the likelihood of adverse reactions.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of Oxyfast (Oxycodone Hydrochloride) is documented by regulatory authorities as a severe, life-threatening emergency primarily characterized by profound Central Nervous System Depression. The officially described clinical presentation often includes the classic triad of symptoms: pinpoint pupils (miosis), respiratory depression (slowed or shallow breathing), and a progression from extreme somnolence to stupor or coma (unresponsiveness). Other documented signs may include skeletal muscle flaccidity, hypotension, and cold, clammy skin.

The most critical and life-threatening outcome documented is Respiratory Arrest, which can rapidly lead to circulatory collapse, cardiac arrest, and ultimately, death. Because of this severe risk, regulatory guidance mandates that anyone who suspects an overdose must seek immediate medical attention.

Emergency Medical Action

If signs of severe overdose occur, such as significantly slowed breathing, blue-colored lips, or difficulty waking, the regulatory instruction is to contact emergency services immediately. The treatment described in official labeling involves the urgent administration of a specific opioid antagonist to reverse effects, followed by symptomatic and supportive treatment. This often includes maintaining adequate ventilation and continuous monitoring of respiratory and cardiovascular function in a hospital setting. An increased risk of toxicity is documented for elderly and debilitated patients, as well as those with severe renal or hepatic impairment.

Therapeutic Uses of Oxyfast

What Oxyfast Treats: Main Uses and Benefits

Oxyfast is commonly used to help with symptomatic relief when pain reaches moderate to severe levels, often signifying conditions where supportive pain management is crucial. This medication is applied in clinical settings that involve acute or disruptive symptom patterns, such as the heightened discomfort experienced following a surgical procedure or major physical trauma.

It is relevant for patients whose symptoms are refractory or resistant to common non-opioid treatments, addressing symptom clusters that become intense when they interfere with daily functioning. This includes its use in specialized scenarios like palliative care and oncology settings to manage persistent pain, and for managing breakthrough pain episodes—sudden, disruptive manifestations that require short-term symptomatic assistance.

The primary role of the medication is to contribute to improved comfort during critical acute phases and helps patients cope more steadily with difficult, unremitting discomfort. The drug's role is characterized by its application in various domains:

“...it is applied across domains where additional symptomatic support is needed to contribute to easing the overall symptom load.”


Quick Fact: Relief for High-Intensity Pain

Property Description
Primary Symptom Targeted Pain reaching moderate to severe intensity levels
Typical Use Contexts Postoperative recovery, acute trauma, oncology care
Main Therapeutic Role Managing pain unresponsive to standard non-opioid options
Benefit Focus Supportive relief during acute and severe symptomatic episodes

Eligibility and Restrictions for Use

Official Eligibility Profile

The eligibility for using Oxyfast (Oxycodone Hydrochloride) is strictly defined by regulatory authorities and centers on patient age, pre-existing conditions, and physiological status. Use is generally restricted to the adult population (18 years and older) requiring management of moderate to severe pain.

Absolute Contraindications

Regulatory documents explicitly state that the medicine must not be used in patients with specific high-risk conditions, including:

  • Significant respiratory depression or acute, severe bronchial asthma.
  • Known or suspected paralytic ileus or other severe gastrointestinal obstruction.
  • Known hypersensitivity to oxycodone or any component of the formulation.

Population Restrictions

Population Group Regulatory Status
Pediatric Patients (<18 years) Not recommended; safety and effectiveness are not established.
Pregnancy/Lactation Not recommended; use during pregnancy may result in Neonatal Opioid Withdrawal Syndrome.
Severe Organ Impairment Conditional use; patients with severe hepatic (liver) or renal (kidney) impairment require caution and monitoring due to increased risk of drug accumulation.
Geriatric Patients Conditional use; caution is required, and a lower starting dose is typically necessary.

What should I know about interactions with other medicines?

Pharmacodynamic and CNS Depressant Risks

Co-administration with other Central Nervous System (CNS) depressants, including specific medicinal product categories like benzodiazepines, sedatives, hypnotics, tranquilizers, and other opioid analgesics, may cause a pharmacodynamic interaction leading to profound sedation, respiratory depression, coma, and death. This restriction officially extends to alcohol (ethanol). Furthermore, using Oxyfast with other serotonergic drugs (e.g., certain antidepressants) poses a documented risk of serotonin syndrome.

Pharmacokinetic and Exposure-Altering Interactions

Oxycodone is subject to pharmacokinetic interaction as its metabolism involves the CYP3A4 and CYP2D6 enzyme pathways. CYP3A4 inhibitors (e.g., ketoconazole, grapefruit juice) increase oxycodone plasma concentrations, raising the documented risk of fatal overdose. Conversely, CYP3A4 inducers (e.g., rifampin, St. John's Wort) decrease plasma concentrations, potentially leading to reduced effectiveness.

Interaction-Related Restrictions and Constraints

Official regulatory documents classify co-administration with Monoamine Oxidase Inhibitors (MAOIs) as contraindicated or to be avoided, requiring a 14-day separation after the MAOI is discontinued. Additionally, mixed agonist/antagonist or partial agonist opioid analgesics (e.g., nalbuphine) are avoided as they may precipitate opioid withdrawal or reduce pain relief. Regulatory notes also indicate that interaction effects may be increased in patients with hepatic or renal impairment due to altered clearance.

Mechanism of Action

Mechanism of Action: How Oxyfast Works

Oxyfast acts by engaging specific biological mechanisms within the nervous system, causing defined alterations in physiological processes.


Targeting mu-Opioid Receptors in the CNS

The mechanism begins as Oxyfast acts as a full agonist by binding to the mu-opioid receptors, which are densely located on nerve cells throughout the central nervous system (CNS), including the spinal cord and brainstem. This molecular interaction is a necessary first step for the drug to initiate its cellular cascade and modulate the transmission of neural impulses.


Modulating Signal Transmission Pathways

Once activated, the receptors trigger a cellular response that reduces the excitability of nerve cells and limits the release of excitatory chemical messengers (neurotransmitters) that carry signals across synapses. This pathway modulation causes a reduction in the speed and intensity of neural communication, resulting in decreased signal transmission to supraspinal pathways.


Influence on Involuntary Physiological Processes

The mechanism of action is also relevant in other systems as mu-opioid receptors are found in centers controlling automatic reflexes in the brainstem and in the gut's enteric nervous system (ENS). Activating these receptors results in alterations in the activity of the medullary cough center and a reduction in gastrointestinal smooth muscle motility.

Dosage and Administration Information

The administration of Oxyfast (Oxycodone Hydrochloride oral solution/concentrate) is strictly governed by instructions focused on precise, scheduled use. The approved and exclusive route is oral ingestion of the immediate-release liquid formulation. Dosing is highly individualized but generally begins in opioid-naïve adults with a range of 5 mg to 15 mg and is subsequently titrated to the lowest effective dosage.

The medicine is prescribed for administration on an as-needed or scheduled basis, with a required interval of every four to six hours between doses. It should not be taken more frequently than six times a day. For chronic management, a fixed schedule is often employed, but the overall duration of use should be the shortest consistent with treatment goals.

Accurate administration requires mandatory use of the calibrated measuring device (oral syringe or cup) provided with the product, a critical procedural step to prevent errors between the milligram (mg) dose and the milliliter (mL) volume. Intake may occur with or independent of meals, though maintaining a consistent relationship with food is recommended.

Special dose adjustments are specified for vulnerable groups: for patients with hepatic or renal impairment, the starting dose should follow a conservative approach, sometimes requiring a 50% reduction. The highest concentration (20 mg/mL) is officially restricted for use in opioid-tolerant patients only.

Recent Clinical Evidence

Research evidence / Overview of Studies for Oxyfast

This section summarizes the published research structure and clinical trials related to immediate-release oxycodone (Oxyfast), focusing on the types of evidence that exist, the populations studied, and what remains unclear. This information describes group patterns observed in studies and does not determine whether an individual will respond similarly.


Evidence for Use in Acute Moderate to Severe Postoperative Pain

The research base for immediate-release oxycodone in this setting includes numerous short-term Randomized Controlled Trials (RCTs) and meta-analyses to assess research findings related to symptom patterns. These studies were relevant in trials assessing short-term or episodic symptom patterns immediately after surgery. The research examined outcomes related to physical discomfort, such as pain intensity scores, and also monitored the requirement for supplemental symptom relief over defined time intervals.

The trials predominantly involved adults who had not regularly used strong pain relievers before and were recovering from various surgical procedures. Results apply only to the populations studied. It is important to note that long-term effects are not fully established regarding the long-term course of symptoms or functional status, as the follow-up durations were limited in these acute care studies, typically only lasting a few days up to one week.


Research in Chronic Pain Conditions

Research exploring this medicine in Chronic Cancer Pain settings includes RCTs that compared immediate-release oxycodone to other strong pain relievers, for conditions where symptoms may vary in intensity. Studies examined functional measures and measures related to sudden, intense breakthrough pain episodes. While studies contribute to the broader evidence landscape for chronic cancer pain research, long-term effects are not fully established beyond the typical intermediate-term follow-up (e.g., three months) in high-quality controlled trials.

For use in Chronic Non-Cancer Pain, the evidence base includes Systematic Reviews and observational settings evaluating daily-life functioning. Evidence is limited for long-term use (extending beyond one year) and the certainty remains low due to high patient dropout rates and reliance on observational data for extended periods.


What Remains Uncertain in the Evidence Base

Subgroup findings are uncertain for specific complex patient populations or those with multiple pre-existing conditions, as these groups are often excluded from the largest trials. Evidence quality varies across studies, particularly in the chronic pain domains where observational data are more common than structured controlled trials. Research highlights what is known—and what is still uncertain—emphasizing that study results reflect the specific conditions under which they were conducted.

Key Studies & References

  1. NICE Guideline on Opioids in chronic pain: long-term monitoring and risk assessment

Frequently Asked Questions (FAQ)

Common questions about Oxyfast (FAQ)


Q: How quickly can someone expect to feel the effects of Oxyfast?

A: According to official product information for the immediate-release liquid formulation, the onset of pain relief is typically described as beginning within 10 to 30 minutes after a dose is administered. This rapid onset is related to its liquid, immediate-release form.

Q: How long does the effect of a single dose of Oxyfast typically last?

A: Studies indicate that the analgesic (pain-relieving) effect of a single dose of the immediate-release oral solution usually lasts for 3 to 6 hours. This duration is consistent with the required dosing interval of every four to six hours mentioned in regulatory instructions.

Q: Does Oxyfast have a high potential for dependency or addiction?

A: Official regulatory documents confirm that as an opioid analgesic and Schedule II controlled substance, this medicine carries an officially documented risk for addiction, abuse, and misuse. Additionally, the prolonged use of any opioid can lead to physical dependence, which may result in withdrawal syndrome if the medicine is stopped too quickly.

Q: What should I do if I miss a scheduled time to use Oxyfast?

A: Regulatory patient counseling information addresses what to do if a dose is missed. If a patient is following a scheduled routine, the general regulatory guidance is to skip the missed dose and return to the regular dosing schedule when the next dose is due. Official guidance notes that patients are instructed not to take a double dose to make up for a missed dose.

Q: Can Oxyfast affect my ability to drive or operate machinery?

A: Yes, official safety information includes a formal warning about driving and operating machinery. The medicine can cause common side effects such as dizziness and somnolence (drowsiness), which may impair judgment. Regulatory information advises caution against driving or operating heavy machinery until a patient knows how the medicine affects them.

Q: Is Oxyfast safe for use during pregnancy or while breastfeeding?

A: The medicine is officially noted as not recommended for use during pregnancy. Official documents note a specific risk that an infant may develop Neonatal Opioid Withdrawal Syndrome after birth if the medicine is used during pregnancy. The active ingredient passes into breast milk, and its use is not recommended during lactation, as stated in the product information.

Q: What is the general duration of treatment with Oxyfast?

A: Regulatory guidance emphasizes that the medicine should be used for the shortest duration of time consistent with the patient's treatment goals. For acute (short-term) conditions, treatment may be needed for only a few days. The determination of the total duration of use is based on individual patient needs as assessed by a healthcare provider.

Q: Can taking a multivitamin or common herbal supplement interact with Oxyfast?

A: Some specific herbal supplements (such as St. John’s Wort) and certain other medicines are known to cause documented drug interactions that can change the amount of medicine in the system. Official guidance strongly advises that patients share a complete list of all medicines, vitamins, and herbal supplements with their healthcare provider.

Q: If I am taking pain relievers, is it safe to use Oxyfast?

A: Regulatory documents include restrictions against using this medicine with other opioid analgesics and specific mixed types of opioids. The combination of the medicine with other pain relievers requires careful evaluation to ensure it aligns with the prescribed treatment plan.

Q: Can I use Oxyfast if I also use medicine for anxiety or depression?

A: Official safety documents list specific risks when combining this medicine with CNS depressants (which include some medicines for anxiety) and serotonergic drugs (which include some medicines for depression). These combinations can cause serious documented effects like profound sedation, severe breathing problems (respiratory depression), and serotonin syndrome.

Q: If I take Oxyfast with food, will it change how it is absorbed?

A: The medicine can be taken with or without food. However, research findings indicate that if the oral solution is taken with a high-fat meal, it can delay the time it takes to reach peak concentration in the blood. Official guidance generally recommends maintaining a consistent relationship with food intake.

Q: Does the strength or dosage of Oxyfast affect the likelihood of side effects?

A: Yes, regulatory guidance states that using a higher dose or increasing the dosage raises the risk of serious side effects, including the most serious one, life-threatening respiratory depression (severe breathing problems). The dosage is individually adjusted to find the amount that is effective for pain while minimizing adverse reactions.

Q: Can I stop using Oxyfast suddenly, or does it need to be done gradually?

A: If a patient has developed physical dependence on the medicine, official patient information advises that it should not be abruptly discontinued. Stopping suddenly can cause severe symptoms of opioid withdrawal. A gradual reduction plan (tapering) is recommended to manage this process.

Q: What is the patient experience generally like when transitioning off Oxyfast?

A: If the body has developed physical dependence, patients may experience symptoms of opioid withdrawal when the dosage is reduced or stopped. These symptoms can include restlessness, muscle aches, anxiety, and insomnia. The process of stopping the medicine is typically managed with monitoring and support to address these effects.

Q: Is there an official patient education resource for Oxyfast?

A: Yes, official regulatory documents, such as the U.S. FDA’s DailyMed, include a Patient Counseling Information section and a Medication Guide. These resources provide critical, officially reviewed information on the medicine’s safe use, risks, and proper disposal.

Q: Is Oxyfast considered a controlled substance in all countries?

A: The active ingredient, oxycodone, is classified as a Controlled Substance (CII) by the U.S. FDA, meaning its use is strictly regulated due to the high risk of abuse and dependence. Most major countries regulate the active ingredient similarly due to international conventions, though specific classification categories may vary by region.

Q: Is there any research evidence on the long-term effects of using Oxyfast?

A: Official research summaries often highlight that long-term effects are not fully established beyond intermediate-term follow-up in clinical trials. For use in chronic pain conditions, evidence for use extending beyond one year is generally limited.

Q: Is there a link between using Oxyfast and mental health changes?

A: Officially documented adverse reactions associated with the medicine include changes in mental state. These documented effects include anxiety, insomnia, confusion, and dysphoria. These are listed as potential side effects in the regulatory safety information.

Q: Does the brand name Oxyfast mean it is a fast-acting version?

A: The official formulation of this medicine is an immediate-release oral solution of oxycodone. This formulation is specifically designed to provide a rapid onset of action for pain relief, distinguishing it from controlled-release or extended-release versions of the same medicine.

Q: What is the consensus among medical bodies regarding the use of Oxyfast?

A: Official medical bodies and regulatory guidelines generally endorse its use for the management of moderate to severe pain when non-opioid options are inadequate. This consensus strongly emphasizes the use of the lowest effective dose for the shortest duration possible due to the associated risks of addiction and dependence.

Q: Can I take Oxyfast at the same time as my blood pressure medication?

A: Official warnings note that this medicine can cause hypotension (low blood pressure). Caution is formally advised when administering it to patients with certain circulatory issues. The potential interaction with other medicines that affect blood pressure is subject to careful evaluation as part of the prescribing process.

Q: Can I use Oxyfast if I have a history of stomach issues or ulcers?

A: The medicine is formally contraindicated (must not be used) in patients with known or suspected paralytic ileus or other severe gastrointestinal obstruction. While not an absolute contraindication, use in patients with other pre-existing gastrointestinal conditions should be approached with caution, as indicated in regulatory documents.

Q: Is there a generic version of Oxyfast available?

A: Regulatory records from agencies such as the U.S. FDA indicate that the active ingredient in this medicine, Oxycodone Hydrochloride, is available as a generic medicine.

How should Oxyfast be stored and disposed of?

How to Store and Dispose of Oxyfast (Oxycodone Hydrochloride Oral Solution)

Official regulatory guidelines define specific requirements for the storage and disposal of Oxyfast to maintain product stability and ensure security.

Required Storage Conditions

Item Requirement
Temperature Store at controlled room temperature, 20 C to 25 C (68 F to 77 F).
Protection Keep the original container tightly closed and protect from light and moisture.
Child-Safety Store securely, out of the sight and reach of children and others, due to the risk of accidental exposure.

Official Disposal Protocol

Expired or unused Oxyfast must be disposed of promptly. The preferred method is to take the medicine to an authorized DEA collector or a medicine take-back program. If a take-back option is not readily available, the unused medication must be disposed of by flushing it down the toilet as instructed for certain opioids.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Oxyfast found in:

A-Z Index: